EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists

Lars Björnebo iD, Shirin Razdan iD, Andrea Discacciati, Thorgerdur Palsdottir iD, Markus Aly iD, Tobias Nordström iD, Martin Eklund iD, Dara Lundon iD, Henrik Grönberg iD, Ash Tewari iD, Peter Wiklund iD, Natasha Kyprianou iD und 1 weitere

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Lars Björnebo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Adrenergic alpha-1 Receptor Antagonists. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background α1-Adrenergic receptor antagonists are commonly used to treat benign prostatic hyperplasia. Preclinical studies suggest that they induce cell death and inhibit tumor growth. This study evaluated the risk of prostate cancer death in men using α1-adrenergic receptor antagonists.

Methods

A population-based cohort study in Stockholm, Sweden (January 1, 2007, to December 31, 2019) included 451 779 men with a prostate-specific antigen test result. Study entry was 1 year after the first prostate-specific antigen test. Men were considered exposed at their second filled prescription. The primary outcome was prostate cancer mortality. Secondary outcomes were all-cause mortality and prostate cancer incidence. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for all outcomes. Inverse-probability weighting with marginal structural models accounted for time-dependent confounders.

Results

Of 351 297 men in the final cohort, 39 856 (11.3%) were exposed to α1-adrenergic receptor antagonists. Median (interquartile range) follow-up for prostate cancer mortality was 8.9 (5.1-10.9) years; median (interquartile range) exposure time to α1-adrenergic receptor antagonists was 4.4 (2.0-7.6) years. There was no evidence of an association between α1-adrenergic receptor antagonist use and prostate cancer mortality, all-cause mortality, or high-grade prostate cancer. α1-Adrenergic receptor antagonist use was associated with an increased risk of prostate cancer (HR = 1.11, 95% CI = 1.06 to 1.17) and low-grade prostate cancer (HR = 1.22, 95% CI = 1.11 to 1.33). Men whose prostate cancer was treated with α1-adrenergic receptor antagonists underwent more frequent prostate-specific antigen testing.

Conclusions

Our findings show no significant association between α1-adrenergic receptor adrenoceptor antagonist exposure and prostate cancer mortality or high-grade prostate cancer. Although the preclinical evidence indicates a potential chemopreventive effect, this study’s findings do not support it.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAdrenergic alpha-1 Receptor AntagonistsHumansMaleAgedSwedenIncidenceMiddle AgedProstate-Specific AntigenCohort StudiesProportional Hazards ModelsProstatic HyperplasiaFollow-Up Studies

Substanzen

Adrenergic alpha-1 Receptor AntagonistsProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Urology, Karolinska University Hospital Solna, Stockholm, Sweden.
  • Department of Oncological Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

ORCID-Profile: Lars Björnebo, Shirin Razdan, Thorgerdur Palsdottir, Markus Aly, Tobias Nordström, Martin Eklund, Dara Lundon, Henrik Grönberg, Ash Tewari, Peter Wiklund, Natasha Kyprianou, Anna Lantz

Förderung

  • NCI NIH HHS
  • Karolinska Institute

Zitieren

APA

Björnebo, L., Razdan, S., Discacciati, A., Palsdottir, T., Aly, M., Nordström, T., Eklund, M., Lundon, D., Grönberg, H., Tewari, A., Wiklund, P., Kyprianou, N., & Lantz, A. (2024). Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae108

Vancouver

Björnebo L, Razdan S, Discacciati A, Palsdottir T, Aly M, Nordström T, et al. Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae108

BibTeX
@article{Bjrnebo2024,
  author = {Björnebo, Lars and Razdan, Shirin and Discacciati, Andrea and Palsdottir, Thorgerdur and Aly, Markus and Nordström, Tobias and Eklund, Martin and Lundon, Dara and Grönberg, Henrik and Tewari, Ash and Wiklund, Peter and Kyprianou, Natasha and Lantz, Anna},
  title = {Prostate cancer incidence and mortality in men exposed to α1-adrenergic receptor antagonists},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae108}
}
Kostenlos starten →